NPS Pharmaceuticals Director Sells $233,288 in Stock (NPSP)
NPS Pharmaceuticals (NASDAQ:NPSP) Director Georges Gemayel sold 6,188 shares of the stock on the open market in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $37.70, for a total value of $233,287.60. Following the completion of the sale, the director now directly owns 9,000 shares of the company’s stock, valued at approximately $339,300. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
NPS Pharmaceuticals (NASDAQ:NPSP) traded down 3.32% on Friday, hitting $37.03. The stock had a trading volume of 1,706,054 shares. NPS Pharmaceuticals has a one year low of $7.35 and a one year high of $38.74. The stock’s 50-day moving average is $34.90 and its 200-day moving average is $28.62. The company’s market cap is $3.781 billion.
Several analysts have recently commented on the stock. Analysts at Zacks reiterated a “neutral” rating on shares of NPS Pharmaceuticals in a research note on Thursday, February 6th. They now have a $34.00 price target on the stock. Separately, analysts at TheStreet upgraded shares of NPS Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday, January 20th. Finally, analysts at Brean Capital raised their price target on shares of NPS Pharmaceuticals from $36.00 to $41.00 in a research note on Thursday, January 9th. Three investment analysts have rated the stock with a hold rating and eleven have assigned a buy rating to the stock. The company currently has an average rating of “Buy” and a consensus target price of $37.86.
NPS Pharmaceuticals, Inc (NASDAQ:NPSP) is a clinical-stage biopharmaceutical company.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.